Acinetobacter Baumannii Response to Cefiderocol Challenge in Human Urine

Abstract excerpt

Cefiderocol (CFDC) is a novel chlorocatechol-substituted siderophore cephalosporin, approved by the Food and Drug Administration (FDA) for treating complicated urinary tract infections and for hospital-acquired and ventilator-acquired pneumonia. In previous work, human serum, human serum albumin,HSA, and human pleural fluid, HPF, were shown to increase the minimum inhibitory concentration (MICs) of Acinetobacter b...

Topics

Open a Topic to create a Post that cites this publication.

• Antibiotic Resistance in Bacteria
• Antibiotics Pharmacokinetics and Efficacy
• Cystic Fibrosis Research Advances
• Dialysis and Renal Disease Management
• Escherichia coli research studies
• Iron Metabolism and Disorders
• Plant Pathogenic Bacteria Studies
• Urinary Tract Infections Management

Identifiers and source

Literature Corpus work

be20f595-7d24-52de-8e7c-4ea944c04bd2

DOI

10.21203/rs.3.rs-1459884/v1